search
Back to results

Lipid Balance in Adult Sickle Cell Patients (HDL2)

Primary Purpose

Sickle Cell Disease, Dyslipidemia, Complication

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
HDL2
Sponsored by
Centre Hospitalier Universitaire de Pointe-a-Pitre
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sickle Cell Disease focused on measuring Sickle cell disease, lipids, vasoocclusive crisis, priapism, pulmonary arterial hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aged from 18 years and over Be affected with Sickle cell anemia or SC sickle cell Living in French Caribbean Islands of Guadeloupe or Martinique and followed by physicians issued from a French West Indies Sickle Cell Reference or Competence Center At steady state in the last month (without acute complication) To have given a written consent after information on the study. Exclusion Criteria: Other hemoglobinopathies than sickle cell disease Pregnancy or lactation Patient under judicial protection or without freedom Patient not affiliated with a social security system Patient hospitalized for transfusion or bleeding in the last 3 months

Sites / Locations

  • Unité Transversale de la DrépanocytoseRecruiting
  • Centre de Référence de la Drépanocytose

Outcomes

Primary Outcome Measures

/ Lipids profiles at steady state, in sickle cell anemia and SC sickle cell adult patients, classified according to occurrence of complications.
Cohorts of sickle cell disease patients include sickle cell anemia (SCA) and SC sickle cell patients living in Guadeloupe and Martinique and followed by the Sickle cell disease (SCD) Reference and Competence Centers of French West Indies. Lipid profile includes total cholesterol, HDL-cholesterol, non-HDL-cholesterol, LDL-cholesterol and triglycerides, apolipoproteins A-I and B. Collection of medical histories and of prospective SCD complications include retinopathy, deafness, tinnitus, osteonecrosis, leg ulcers, strokes, acute chest syndrome, VOC, priapism, pulmonary arterial hypertension (PAH) and PAH sd (echocardiography diagnosed when tricuspid regurgitant jet velocity ≥2.5 m/sec), kidney disease: chronic renal insufficiency and/or nephropathy

Secondary Outcome Measures

Kinetic study of lipids profile during hospitalized vasoocclusive crisis (VOC, with or without ACS) and Priapism, at return to steady state at first annual check-up, and one year after this last measurement
Past and prospective collection of previously listed SCD complications
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
total cholesterol
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
HDL-cholesterol
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
non HDL-cholesterol
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
LDL-cholesterol
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
triglycerides
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Apolipoproteins A-I and B
Description of genetic primary modulators of SCD complications.
Fetal hemoglobin,
Description of genetic primary modulators of SCD complications.
alpha-thalassemia,
Description of genetic primary modulators of SCD complications.
haplotypes of beta S gene
Dosages of Insulin resistance (HOMA),
Plasmatic insulinemia and glycemia (HOMA) will be performed in the entire cohort at inclusion and during prospective complications (VOC, priapism); lipids dosages
free fatty acids
kinetic study of free fatty acids at inclusion and during prospective complications (VOC, priapism);
plasmatic glycerol.
Kinetic study of plasmatic at inclusion and during prospective complications (VOC, priapism);
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of CETP (Cholesteryl Ester Transfer Protein) enzymes activities
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of L-CAT (Lécithine Cholestérol Acyl Transférase) enzymes activities
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of HDL lipidome,
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of HDL functionality,
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of free fatty acid
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
The dosages of glycerol

Full Information

First Posted
December 12, 2022
Last Updated
March 21, 2023
Sponsor
Centre Hospitalier Universitaire de Pointe-a-Pitre
Collaborators
Direction Générale de l'Offre de Soins
search

1. Study Identification

Unique Protocol Identification Number
NCT05780775
Brief Title
Lipid Balance in Adult Sickle Cell Patients
Acronym
HDL2
Official Title
Study of Lipid Balance in Adult Sickle Cell SS or SC Patients at Steady State and According to Clinical Phenotypes and During Acute Complications Acronym : "HDL2"
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2022 (Actual)
Primary Completion Date
November 30, 2028 (Anticipated)
Study Completion Date
November 30, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Pointe-a-Pitre
Collaborators
Direction Générale de l'Offre de Soins

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to describe and/or searches for, in cohorts of adult sickle cell anemia (SCA) and SC sickle cell patients living in the French West Indies and followed by SCD Reference and Competence Centers: 1-lipids profiles and associations at steady state with occurrence of sickle cell disease (SCD) complications, 2-lipids profile evolution during and after prospective acute complications (vasoocclusive crises (VOC) and priapism), 3-lipids profile variation (inter /intra individuals) during 4 prospective years, 4- Genetic primary modulators of SCD complications, 5- insulin resistance (HOMA), free fatty acids and glycerol dosages, 6- lipids enzymes, lipidome and functionality of HDL in sub-groups of SCD population.
Detailed Description
Cohorts of sickle cell disease patients including sickle cell anemia (SCA) and SC sickle cell patients living in Guadeloupe and Martinique and followed by the Sickle cell disease (SCD) Reference and Competence Centers of French West Indies. Lipid profile includes total cholesterol, HDL-cholesterol, non-HDL-cholesterol, LDL-cholesterol and triglycerides, apolipoprotein A-I and B. Medical histories and prospective collection of SCD complications include retinopathy, deafness, tinnitus, osteonecrosis, leg ulcers, strokes, acute chest syndrome, VOC, priapism, pulmonary arterial hypertension (PAH) and PAH sd (echocardiography diagnosed when tricuspid regurgitant jet velocity ≥2.5 m/sec), kidney disease: chronic renal insufficiency and/or nephropathy. Objective 4: to describe genetic primary modulators of SCD complications: fetal hemoglobin, alpha-thalassemia, haplotypes of beta S gene. Objective 5 will be performed in the entire cohort at inclusion and during prospective complications (VOC, priapism). Objective 6 will be performed in a sub-group of 90 individuals (n=15 with VOC and n= 15 without VOC, n=15 with priapism and n=15 without priapism, n= 15 with pulmonary arterial hypertension syndrome (PAH Sd) and n=15 without PAH Sd), as well as in a subgroup of n = 15 patients prospectively experiencing VOC and n = 15 patients prospectively experiencing priapism. A collection of plasma is performed to fulfill objective 6, as well as a collection of blood cells for later researches.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease, Dyslipidemia, Complication
Keywords
Sickle cell disease, lipids, vasoocclusive crisis, priapism, pulmonary arterial hypertension

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
350 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
HDL2
Other Intervention Name(s)
collection of plasma and of cells.
Intervention Description
to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
Primary Outcome Measure Information:
Title
/ Lipids profiles at steady state, in sickle cell anemia and SC sickle cell adult patients, classified according to occurrence of complications.
Description
Cohorts of sickle cell disease patients include sickle cell anemia (SCA) and SC sickle cell patients living in Guadeloupe and Martinique and followed by the Sickle cell disease (SCD) Reference and Competence Centers of French West Indies. Lipid profile includes total cholesterol, HDL-cholesterol, non-HDL-cholesterol, LDL-cholesterol and triglycerides, apolipoproteins A-I and B. Collection of medical histories and of prospective SCD complications include retinopathy, deafness, tinnitus, osteonecrosis, leg ulcers, strokes, acute chest syndrome, VOC, priapism, pulmonary arterial hypertension (PAH) and PAH sd (echocardiography diagnosed when tricuspid regurgitant jet velocity ≥2.5 m/sec), kidney disease: chronic renal insufficiency and/or nephropathy
Time Frame
6 years
Secondary Outcome Measure Information:
Title
Kinetic study of lipids profile during hospitalized vasoocclusive crisis (VOC, with or without ACS) and Priapism, at return to steady state at first annual check-up, and one year after this last measurement
Description
Past and prospective collection of previously listed SCD complications
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
total cholesterol
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
HDL-cholesterol
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
non HDL-cholesterol
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
LDL-cholesterol
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
triglycerides
Time Frame
6 years
Title
Study of variation of lipid profile, at steady state, during a 4 years period study intra and inter individual levels.
Description
Apolipoproteins A-I and B
Time Frame
6 years
Title
Description of genetic primary modulators of SCD complications.
Description
Fetal hemoglobin,
Time Frame
6 years
Title
Description of genetic primary modulators of SCD complications.
Description
alpha-thalassemia,
Time Frame
6 years
Title
Description of genetic primary modulators of SCD complications.
Description
haplotypes of beta S gene
Time Frame
6 years
Title
Dosages of Insulin resistance (HOMA),
Description
Plasmatic insulinemia and glycemia (HOMA) will be performed in the entire cohort at inclusion and during prospective complications (VOC, priapism); lipids dosages
Time Frame
6 years
Title
free fatty acids
Description
kinetic study of free fatty acids at inclusion and during prospective complications (VOC, priapism);
Time Frame
6 years
Title
plasmatic glycerol.
Description
Kinetic study of plasmatic at inclusion and during prospective complications (VOC, priapism);
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of CETP (Cholesteryl Ester Transfer Protein) enzymes activities
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of L-CAT (Lécithine Cholestérol Acyl Transférase) enzymes activities
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of HDL lipidome,
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of HDL functionality,
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of free fatty acid
Time Frame
6 years
Title
Dosages of lipids enzymes, lipidome and functionality of HDL at steady state
Description
The dosages of glycerol
Time Frame
6 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged from 18 years and over Be affected with Sickle cell anemia or SC sickle cell Living in French Caribbean Islands of Guadeloupe or Martinique and followed by physicians issued from a French West Indies Sickle Cell Reference or Competence Center At steady state in the last month (without acute complication) To have given a written consent after information on the study. Exclusion Criteria: Other hemoglobinopathies than sickle cell disease Pregnancy or lactation Patient under judicial protection or without freedom Patient not affiliated with a social security system Patient hospitalized for transfusion or bleeding in the last 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Valérie HAMONY-SOTER
Phone
+590 590934686
Email
valerie.soter@chu-guadeloupe.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Eunice Nubret
Phone
+590 590 93 46 86
Email
eunice.nubret@chu-guadeloupe.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Laure LALANNE-MISTRIH
Organizational Affiliation
: University Hospital of Guadeloupe - Department of Nutrition
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unité Transversale de la Drépanocytose
City
Pointe-à-Pitre
State/Province
Guadeloupe
ZIP/Postal Code
97159
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maryse ETIENNE JULAN
Phone
+590 590 93 46 70
Email
maryse.etienne-julan@chu-guadeloupe.fr
First Name & Middle Initial & Last Name & Degree
Maryse ETIENNE JULAN
Facility Name
Centre de Référence de la Drépanocytose
City
Le Lamentin
State/Province
Martinique
ZIP/Postal Code
97292
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gylna LOKO
Phone
+596 596 48 00 00
Email
gylna.loko@gmail.com
First Name & Middle Initial & Last Name & Degree
Gylna LOKO

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lipid Balance in Adult Sickle Cell Patients

We'll reach out to this number within 24 hrs